| Secondary | Panel A: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) After Administration of 6mg of MK-1167 | AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC0-24 value was presented for Panel A participants after administration of 6mg of MK-1167. | All Panel A randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | 95% Confidence Interval | μM*hour | | Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Secondary | Panel A: AUC0-24 After Administration of 3mg of MK-1167 | AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC 0-24 value was presented for Panel A participants after administration of 3mg of MK-1167. | All Panel A randomized participants who received at least one dose of study treatment (3mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | 95% Confidence Interval | μM*hour | | Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 3mg QD + Donepezil 10mg QD | After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21. |
| |
| Secondary | Panel B: AUC0-24 After Administration of 6mg of MK-1167 | AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC0-24 value was presented for Panel B participants after administration of 6mg of MK-1167. | All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | 95% Confidence Interval | μM*hour | | Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |
| Secondary | Panel A: Maximum Plasma Concentration (Cmax) After Administration of 6mg of MK-1167 | Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel A participants after administration of 6mg of MK-1167. | All Panel A randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | 95% Confidence Interval | μmol/Liter | | Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21. |
| |
| Secondary | Panel A: Cmax After Administration of 3mg of MK-1167 | Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel A participants after administration of 3mg of MK-1167. | All Panel A randomized participants who received at least one dose of study treatment (3mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | 95% Confidence Interval | μmol/Liter | | Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 3mg QD + Donepezil 10mg QD | After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21. |
| |
| Secondary | Panel B: Cmax After Administration of 6mg of MK-1167 | Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel B participants after administration of 6mg of MK-1167. | All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | 95% Confidence Interval | μmol/Liter | | Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |
| Secondary | Panel A: Plasma Concentration at 24 Hours (C24) After Administration of 6mg of MK-1167 | C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel A participants after administration of 6mg of MK-1167. | All Panel A randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | 95% Confidence Interval | μmol/Liter | | Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21. |
| |
| Secondary | Panel A: C24 After Administration of 3mg of MK-1167 | C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel A participants after administration of 3mg of MK-1167. | All Panel A randomized participants who received at least one dose of study treatment (3mg MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | 95% Confidence Interval | μmol/Liter | | Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 3mg QD + Donepezil 10mg QD | After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21. |
| |
| Secondary | Panel B: C24 After Administration of 6mg of MK-1167 | C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel B participants after administration of 6mg of MK-1167. | All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | 95% Confidence Interval | μmol/Liter | | Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |
| Primary | Number of Participants Who Experienced an Adverse Event (AE) | An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported. | All randomized participants who received at least one dose of study treatment. | Posted | | Count of Participants | | Participants | | Up to approximately 7 weeks | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21. | | OG001 | Panel A: MK-1167 3mg QD + Donepezil 10mg QD | After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21. | | OG002 | Panel A: Placebo to MK-1167 + Donepezil 10mg QD | Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21. |
|
| Primary | Number of Participants Who Discontinued Study Treatment Due to an AE | An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE were reported. | All randomized participants who received at least one dose of study treatment. | Posted | | Count of Participants | | Participants | | Up to approximately 4 weeks | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6 mg MK-1167 oral loading doses QD Days 1 to 7. Participants also received 10mg oral Donepezil on Days -3 to 21. | | OG001 | Panel A: MK-1167 3mg QD + Donepezil 10mg QD | After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21. | | OG002 | Panel A: Placebo to MK-1167 + Donepezil 10mg QD | |
|
| Secondary | Panel A: Time to Maximum Plasma Concentration (Tmax) After Administration of 6mg of MK-1167 | Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel A participants after administration of 6mg of MK-1167. | All Panel A randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Median | Full Range | hours | | Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21. |
| |
| Secondary | Panel A: Tmax After Administration of 3mg of MK-1167 | Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel A participants after administration of 3mg of MK-1167. | All Panel A randomized participants who received at least one dose of study treatment (3mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Median | Full Range | hours | | Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 3mg QD + Donepezil 10mg QD | After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21. |
| |
| Secondary | Panel B: Tmax After Administration of 6mg of MK-1167 | Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel B participants after administration of 6mg of MK-1167. | All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Median | Full Range | hours | | Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |
| Secondary | Panel A: Apparent Clearance (CL/F) After Administration of 3mg of MK-1167 | CL/F is the rate at which the MK-1167 is completely removed from plasma. Blood samples were collected at pre-specified intervals for the determination of CL/F. Per protocol, CL/F was based on noncompartmental analysis, and a geometric mean CL/F value was presented for Panel A participants after administration of 3mg of MK-1167. | All Panel A randomized participants who received at least one dose of study treatment (3mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Liter/hour | | Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 3mg QD + Donepezil 10mg QD | After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21. |
| |
| Secondary | Panel B: CL/F After Administration of 6mg of MK-1167 | CL/F is the rate at which the MK-1167 is completely removed from plasma. Blood samples were collected at pre-specified intervals for the determination of CL/F. Per protocol, CL/F was based on noncompartmental analysis, and a geometric mean CL/F value was presented for Panel B participants after administration of 6mg of MK-1167. | All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Liter/hour | | Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |
| Secondary | Panel A: Apparent Terminal Half-Life (t1/2) After Administration of 3mg of MK-1167 | t1/2 is defined as the time required to divide plasma concentration of MK-1167 by half after reaching pseudo-equilibrium. Blood samples were collected at pre-specified intervals for the determination of t1/2. Per protocol, t1/2 was based on noncompartmental analysis, and a geometric mean t1/2 value was presented for Panel A participants after administration of 3mg of MK-1167. | All Panel A randomized participants who received at least one dose of study treatment (3mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | Geometric Coefficient of Variation | hours | | Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 3 mg QD + Donepezil 10mg QD | After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21. |
| |
| Secondary | Panel B: t1/2 After Administration of 6mg of MK-1167 | t1/2 was defined as the time required to divide plasma concentration of MK-1167 by half after reaching pseudo-equilibrium. Blood samples were collected at pre-specified timepoints for the determination of t1/2. Per protocol, t1/2 was based on noncompartmental analysis, and a geometric mean t1/2 value was presented for Panel B participants after administration of 6mg of MK-1167. | All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | Geometric Coefficient of Variation | hour | | Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |
| Secondary | Panel A: Apparent Volume of Distribution (Vz/F) After Administration of 3mg of MK-1167 | Vz/F was the apparent volume of distribution of MK-1167. Blood samples were collected at pre-specified intervals for the determination of Vz/F. Per protocol, Vz/F was based on noncompartmental analysis, and a geometric mean Vz/F value was presented for Panel A participants after administration of 3mg of MK-1167. | All Panel A randomized participants who received at least one dose of study treatment (3mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Liter | | Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel A: MK-1167 3mg QD + Donepezil 10mg QD | After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21. |
| |
| Secondary | Panel B: Vz/F After Administration of 6mg of MK-1167 | Vz/F was the apparent volume of distribution of MK-1167. Blood samples were collected at pre-specified intervals for the determination of Vz/F. Per protocol, Vz/F was based on noncompartmental analysis, and a geometric mean Vz/F value was presented for Panel B participants after administration of 6mg of MK-1167. | All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Liter | | Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |
| Secondary | Panel B: Day 23 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167 | Blood samples were collected at pre-specified timepoints to determine AUC0-24 on Days 1 and 23. AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 AUC0-24/Day 1 AUC0-24. | All Panel B randomized participants who received at least one dose of study treatment and had AUC0-24 data available for assessment on Day 1 and Day 23. | Posted | | Geometric Mean | 90% Confidence Interval | Ratio | | Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |
| Secondary | Panel B: Day 31 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167 | Blood samples were collected at pre-specified timepoints to determine AUC0-24 on Days 1 and 31. AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 AUC0-24/Day 1 AUC0-24. | All Panel B randomized participants who received at least one dose of study treatment and had AUC0-24 data available for assessment on Day 1 and Day 31. | Posted | | Geometric Mean | 90% Confidence Interval | Ratio | | Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |
| Secondary | Panel B: Day 23 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167 | Blood samples were collected at pre-specified timepoints to determine Cmax on Days 1 and 23. Cmax was defined as the maximum serum concentration of MK-1167 reached. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 Cmax/Day 1 Cmax. | All Panel B randomized participants who received at least one dose of study treatment and had at Cmax data available for assessment on Day 1 and Day 23. | Posted | | Geometric Mean | 90% Confidence Interval | Ratio | | Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |
| Secondary | Panel B: Day 31 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167 | Blood samples were collected at pre-specified timepoints to determine Cmax on Days 1 and 31. Cmax was defined as the maximum serum concentration of MK-1167 reached. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 Cmax/Day 1 Cmax. | All Panel B randomized participants who received at least one dose of study treatment and had at Cmax data available for assessment on Day 1 and Day 31. | Posted | | Geometric Mean | 90% Confidence Interval | Ratio | | Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |
| Secondary | Panel B: Day 23 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167 | Blood samples were collected at pre-specified timepoints to determine C24 on Days 1 and 23. C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 C24/Day 1 C24. | All Panel B randomized participants who received at least one dose of study treatment and had C24 data available for assessment on Day 1 and Day 23. | Posted | | Geometric Mean | 90% Confidence Interval | Ratio | | Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |
| Secondary | Panel B: Day 31 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167 | Blood samples were collected at pre-specified timepoints to determine C24 on Days 1 and 31. C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 C24/Day 1 C24. | All Panel B randomized participants who received at least one dose of study treatment and had C24 data available for assessment on Day 1 and Day 31. | Posted | | Geometric Mean | 90% Confidence Interval | Ratio | | Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31. |
| |